Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.
Clare
C
Bedwell
David
D
Rowe
Deborah
D
Moulton
Gail
G
Jones
Nick
N
Bown
Chris M
CM
Bacon
D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000473:pathology*; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic / Q000235:genetics; D033921:Vesicular Transport Proteins / Q000235:genetics*
D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C507455:SEC31A protein, human; D033921:Vesicular Transport Proteins; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases